Informing Pain Treatment Using Pharmacogenomic Analysis (NCT06511401)
C-PAIN: Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
Who can join: Review the eligibility criteria below.
Location: University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
- Pharmacogenomic (PGx) results. (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (855) 702-8222
Email: cancerclinicaltrials@bsd.uchicago.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Adult Patients Who Are Receiving Oncologic Care clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.